SOURCE: Cardima, Inc.

November 30, 2007 09:30 ET

Cardima Appoints Dr. Sung Chun as Chief Medical Officer

FREMONT, CA--(Marketwire - November 30, 2007) - Cardima, Inc. (OTCBB: CADM), developer of the REVELATION® Tx, REVELATION® T-Flex ablation microcatheters and INTELLITEMP® Energy Management Device, announces today the appointment of Sung Chun, MD as its Chief Medical Officer. Dr. Chun completed his cardiology training at Stanford University School of Medicine and is a cardiologist specializing in electrophysiology. He went onto become an Assistant Professor and Associate Director of Cardiac Arrhythmia Service at Stanford University Medical Center. He is currently the Director of Cardiac Arrhythmia Services, Palo Alto Medical Foundation. Dr. Chun has participated in many of the important electrophysiology trials. He has also published widely in leading medical journals and made important contributions to research in this field.

Dr. Chun has a long association with Cardima having assisted the Company in clinical trials and product design and enhancements.

In commenting on Dr. Chun's appointment, Cardima's Chairman, Tony Shum said, "Cardima is fortunate to have someone of Dr. Chun's qualifications and experience as our Chief Medical Officer. Dr. Chun makes a wonderful addition to the Cardima team and he will be invaluable to us as we begin commercializing our products."

About Cardima

Cardima, Inc. has developed the PATHFINDER® Series of diagnostic catheters, the REVELATION® Series of ablation catheters, the INTELLITEMP® Energy Management Device, and the Surgical Ablation System (SAS). All of these devices are CE marked and received U.S. FDA 510(k) clearance. The REVELATION® Series with the INTELLITEMP® EP Energy Management Device was developed for the treatment of atrial fibrillation (AF) and received CE mark approval in Europe, however, is not currently available in the U.S.

For more information, please visit the Company's website at

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by such forward-looking statements. Potential risks and uncertainties include: the uncertainties associated with the prospects for FDA approval of any new devices; the prospect for any future clinical trials or regulatory activities; the risk that the Company will not be able to raise additional capital in the immediate term as needed to continue operations and the risk that we will be unable to secure a strategic transaction involving the Surgical Ablation System. Additional risks and uncertainties are set forth in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006, the Company's Quarterly Report on Form 10-QSB for the third quarter ended September 30, 2007, and in the Company's subsequent SEC filings. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.

Contact Information